Gemtuzumab Ozogamicin
Gemtuzumab Ozogamicin
Definition
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)
Also known as Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, GEMTUZUMAB OZOGAMICIN, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676 — per NCIT
Also identified as
- ATC L01FX02 per RXNORM
- NCIT NCIT:C1806 per NCIT
- SCTID 127964000 per RXNORM
- SCTID 386640004 per RXNORM
- UNII 8GZG754X6M per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Acute myeloid leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.